Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Melanotan-I

Afamelanotide, MT-I, [Nle4-D-Phe7]-α-MSH, Scenesse, CUV-1647

Quick Stats
Studies 225
Trials 100
Score 3
2008 pubmed 21 citations

Corticotropin-releasing factor (CRF) is involved in the acute anorexic effect of alpha-melanocyte-stimulating hormone: a study using CRF-deficient mice.

Kawashima. Shoko S; Sakihara. Satoru S; Kageyama. Kazunori K; Nigawara. Takeshi T; Suda. Toshihiro T

Key Findings

  • CRF signaling is required for the immediate (0‑4 h) anorexic effect of an alpha‑MSH analogue.
  • Blocking CRF receptors stops the early appetite‑suppressing effect.
  • The later (4‑12 h) appetite suppression occurs even without CRF or glucocorticoids.

Practical Outcomes

  • If you use melanotan‑I for appetite control, expect the initial hunger drop to involve stress hormones, which could affect mood or stress levels. The continued appetite reduction later on is independent of that pathway, suggesting a more stable effect but also indicating that CRF‑related side effects may be limited to the early phase.

Summary

The study shows that the short‑term appetite‑blocking effect of an alpha‑MSH drug like melanotan‑I depends on the stress hormone CRF, while the longer‑lasting effect does not. This means the quick hunger‑reduction you might feel is linked to stress pathways, but the later, sustained reduction works through a different route.

Abstract

Alpha-melanocyte-stimulating hormone (alpha-MSH) and its receptors are critical and indispensable for maintaining appropriate feeding behavior and energy homeostasis in both mice and humans. Corticotropin-releasing factor (CRF) is a candidate for mediating the anorexic effect of alpha-MSH. In the present study, we examined whether CRF and its receptors are involved in the anorexic effect of alpha-MSH, using CRF-deficient (CRFKO) mice and a CRF receptor antagonist. Intracerebroventricular administration of NDP-MSH, a synthetic alpha-MSH analogue, suppressed food intake in wild-type (WT) mice. This effect was abolished by pretreatment with a non-selective CRF receptor antagonist, astressin, suggesting that the effect of alpha-MSH-induced anorexia was mediated by a CRF receptor. In CRFKO mice, administration with NDP-MSH did not affect food intake at an early phase (0-4h). In addition, CRF mRNA levels in the hypothalamus were significantly increased in NDP-MSH-treated mice. Therefore, our findings, using CRFKO, strongly support evidence that CRF is involved in the acute anorexic effect of alpha-MSH. On the other hand, NDP-MSH administered to CRFKO mice led to suppressed food intake at the late phase (4-12h), similar to the effect in WT mice. Further, NDP-MSH similarly reduced food intake during the late phase in all types of mice, including WT, CRFKO, and CRFKO with corticosterone replacement. The results would suggest that alpha-MSH-induced suppression of food intake at late phase was independent of glucocorticoids and CRF.

Study Information

Provider

pubmed

Year

2008

Date

2008-09-26T00:00:00.000Z

DOI

10.1016/j.peptides.2008.09.010

Citations

21

References

44